All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000213-19 | Sertindole versus Risperidone safety outcome study: a randomised, partially-blinded, parallel-group, active-controlled, post-marketing study | 2008-01-21 | due-trials |
| Reported results | 2004-000320-32 | A double-blind, randomised, multicenter, fixed-dose study comparing the efficacy of escitalopram (20mg/day) with that of citalopram (40mg/day) in patients with Major Depressive Disorder | 2010-04-16 | due-trials |
| Completed, but no date, and reported results | 2004-000707-18 | A 40-week open, flexible dose, extension study of bifeprunox in patients with schizophrenia. | bad-data | |
| Reported results | 2004-000990-78 | A Double-Blind, Multicentre, Randomised, Parallel-group, Placebo-controlled Study Assessing the Efficacy and Safety of Escitalopram in Post-Myocardial Infarction Patients Suffering from Depressive Sym... | 2005-06-03 | due-trials |
| Completed, but no date, and reported results | 2004-001264-45 | Protocol title study No. 10402: A 12-month Phase III safety study of gaboxadol 10 mg daily consisting of a 6-month double-blind, randomised, placebo-controlled, parallel-group periodfollowed by a 6-... | bad-data | |
| Completed, but no date, and reported results | 2004-001265-18 | Protocol title No.10403: A double-blind, randomised, placebo-controlled, parallel-group, Phase III study evaluating the efficacy and safety of gaboxadol 5 mg and 10 mg daily in elderly outpatients wit... | bad-data | |
| Reported results | 2004-002185-38 | A 6 months double-blind, risperidone-referenced, flexible dose, parallel-group extension study of bifeprunox in patients with schizophrenia Estudio de extensión de 6 meses con bifeprunox, doble cie... | 2006-03-24 | due-trials |
| Ongoing | 2004-002591-42 | A pharmacoeconomic study conducted in parallel with clinical trial 10200, a 24-week double-blind, risperidone-referenced, flexible dose, parallel-group extension study of bifeprunox in patients with s... | not-yet-due | |
| Reported results | 2004-002614-10 | A 1-Year Randomised, Double-Blind Placebo-Controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients with Alzheimer’s Disease | 2009-02-12 | due-trials |
| Reported results | 2004-005069-39 | A double blind, randomised, multicenter, comparative study of escitalopram and duloxetine in outpatients with Major Depressive Dissorder | 2006-11-10 | due-trials |
| Reported results | 2005-000497-50 | An open-label safety study of bifeprunox investigating flexible doses of 20, 30, or 40mg/day in patients with schizophrenia who have completed studies 10206 or 10265 | 2008-07-21 | due-trials |
| Reported results | 2005-002038-36 | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson s disease dementia or dementia with Lewy Bodies | 2009-01-29 | due-trials |
| Not reported Terminated | 2005-005499-34 | A double-blind, randomised, placebo-controlled, quetiapine-referenced, multicentre study of the long-term bifeprunox efficacy, safety and tolerability in patiens with stable schizophrenia | 2007-05-04 | due-trials |
| Listed as ongoing, but also has a completion date | 2006-000860-10 | An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer’s Disease | 2006-09-04 | bad-data |
| Reported results | 2006-001515-29 | Double-blind, randomised, placebo-controlled study comparing the efficacy and safety of two fixed dosages of a novel antidepressant compound to that of placebo in patients with Major Depressive Disor... | 2008-10-03 | due-trials |
| Reported results | 2006-003739-57 | A double-blind, randomised, parallel-group, placebo-controlled study investigating the safety- and tolerability following fixed oral dose regimens (daily versus twice weekly administration) of Lu 31-1... | 2009-11-06 | due-trials |
| Exempt, with results | 2006-004530-33 | Rasagiliinin ja essitalopraamin yhteiskäytön turvallisuus | 2016-08-23 | not-yet-due |
| Reported results | 2007-000905-31 | A long term open label, flexiable dose, extension study evaluationg the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder | 2008-10-07 | due-trials |
| Reported results | 2007-001071-11 | Randomised, double-blind, parallel-group, placebo-controlled, duloxetine referenced, dose-finding study of Lu AA24530 in Major Depressive Disorder | 2009-03-13 | due-trials |
| Reported results Terminated | 2007-001097-90 | A one-year multinational, multi-centre, randomised, double-blind, parallel-group, fixed-dose, bifeprunox study combining a 12 week placebo-controlled, quetiapine-referenced phase with a 12-month queti... | 2009-06-19 | due-trials |
| Reported results | 2007-001870-95 | A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of three dosages of Lu AA21004, in acute treatment of Major D... | 2009-04-02 | due-trials |
| Reported results | 2007-001871-13 | A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with two doses of Lu AA21004 in patients with Major Depressive Disorder. | 2009-09-07 | due-trials |
| Reported results | 2007-002160-10 | A prospective, open-label, single arm, multinational, multi-centre, flexible dose, extension study of the SCoP 99824 with sertindole for patients suffering from schizophrenia | 2007-07-26 | due-trials |
| Reported results | 2007-002315-92 | A 52-week, randomised, double-blind, placebo-controlled, parallel-group, safety and tolerability study of nalmefene, as needed use, in patients with alcohol dependence | 2010-11-03 | due-trials |
| Reported results | 2007-002334-11 | Nalmefene Efficacy Study I: Randomised, double-blind, placebo-controlled, parallel-group, efficacy study of 20 mg nalmefene, as needed use, in patients with alcohol dependence | 2010-10-14 | due-trials |
| Reported results | 2007-002551-17 | Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo in t... | 2009-10-30 | due-trials |
| Reported results | 2007-002563-27 | Estudio II de eficacia de Nalmefene: Estudio de eficacia aleatorizado, doble ciego, controlado por placebo, de grupo paralelo, con 20 mg de nalmefene, según se necesite, en pacientes con dependencia d... | 2011-03-22 | due-trials |
| Completed, but no date, and reported results | 2007-004009-93 | Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram Prevalenza di depressione, disturbi d'ansia e di controllo... | bad-data | |
| Reported results | 2007-004322-24 | Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome. | 2010-04-23 | due-trials |
| Reported results | 2007-004350-82 | Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox Gastaut Syndrome | 2012-09-18 | due-trials |
| Reported results | 2007-004992-21 | A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder | 2010-03-23 | due-trials |
| Reported results | 2007-007025-51 | A randomised, double-blind, parallel-group, placebo-controlled and active-referenced study evaluating the efficacy and safety of three fixed dose regimens of Lu AA34893 in the treatment of Major Depre... | 2009-04-14 | due-trials |
| Reported results | 2008-000479-11 | A randomised, double-blind, parallel-group, active-controlled, flexible dose study exploring the efficacy and safety of 12 weeks treatment with Lu 31-130 in patients with schizophrenia | 2009-02-06 | due-trials |
| Reported results | 2008-000506-36 | Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose comparison study of escitalopram in combination with two fixed doses of gaboxadol to escitalopram in Major Depressive Disorder | 2009-12-18 | due-trials |
| Reported results | 2008-000622-40 | A randomised, double-blind, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke. | 2014-07-07 | due-trials |
| Reported results | 2008-001441-26 | A randomised, double-blind, parallel-group, fixed dose study exploring the efficacy and safety of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia. | 2010-01-15 | due-trials |
| Reported results | 2008-001673-15 | A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD) | 2010-06-14 | due-trials |
| Completed, but no date, and reported results | 2008-002164-34 | Randomised, double-blind, 3-way crossover, single dose, placebo-controlled study investigating the effect on postural instability of melatonin and zolpidem in healthy elderly subjects | bad-data | |
| Reported results | 2008-002901-38 | Randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed dose study comparing the efficacy and safety of Lu AA21004 in acute treatment of major depressive disorder in... | 2010-02-03 | due-trials |
| Reported results | 2008-003662-25 | Randomised, double blind, placebo controlled study of Lu AA24493 in patients with Friedreich's Ataxia to evaluate safety and tolerability and to explore efficacy | 2011-03-11 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2008-005353-38 | Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major depressive disorder ... | 2022-01-21 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2008-005354-20 | Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 12 to 17 years, with Major depressive disorder... | 2021-03-31 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2008-005356-25 | Long-term, open-label, flexible-dose, extension study of vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 18 years of age | 2022-04-19 | bad-data |
| Reported results | 2008-005539-14 | A randomised, double-blind, parallel-group placebo-controlled phase lll study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke | 2014-10-07 | due-trials |
| Completed, but no date, and reported results | 2009-011144-19 | A randomised, double-blind, placebo-controlled study to evaluate if rasagiline can improve depressive symptoms and cognitive function in non-demented, idiopathic Parkinson s disease patients. | bad-data | |
| Reported results | 2009-011845-24 | Estudio aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, de Lu AE58054 a dosis fijas en pacientes con enfermedad de Alzheimer moderada tratados con donepezilo | 2011-12-23 | due-trials |
| Reported results | 2009-017523-26 | A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of ad... | 2011-12-12 | due-trials |
| Reported results | 2010-020170-42 | An open-label study evaluating the Pharmacokinetics and Tolerability of Lu AA21004 in connection with multiple oral dosing of Lu AA21004 in child and adolescent patients with a DSM-IV-TRTM diagnosis o... | 2014-12-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-020493-42 | A Double-blind, Randomized, Placebo-controlled, Multicentre, Relapse-prevention Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder | 2022-04-28 | bad-data |
| Reported results | 2010-022181-28 | A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophrenia | 2012-10-09 | due-trials |
| Reported results | 2010-024198-38 | A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 (15 and 20 mg/day) in patients with Major Depressive Disorder | 2012-09-28 | due-trials |
| Reported results | 2011-001572-19 | Randomised, double-blind, parallel-group, placebo-controlled, fixed dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult patients with Major Depressive Disorder (MDD) | 2013-05-20 | due-trials |
| Reported results | 2011-001839-23 | Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of Lu AA21004 on cognition and BOLD fMRI signals in subjects remitted from depr... | 2013-09-12 | due-trials |
| Reported results | 2011-002362-21 | A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder ... | 2012-12-20 | due-trials |
| Reported results Terminated | 2012-001361-32 | Interventional, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of brexpiprazole (1 and 3 mg/day) as adjunctive treatment in elderly ... | 2014-05-22 | due-trials |
| Reported results | 2012-001380-76 | Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole as adju... | 2016-06-08 | due-trials |
| Reported results | 2012-002252-17 | Interventional, randomised, double-blind, parallel-group, placebo-controlled, active-reference, flexible-dose study of brexpiprazole in patients with acute schizophrenia | 2015-12-17 | due-trials |
| Reported results | 2012-002705-21 | Interventional, open-label, flexible-dose extension study of brexpiprazole in patients with schizophrenia | 2015-12-30 | due-trials |
| Reported results | 2012-002785-12 | A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia | 2015-01-16 | due-trials |
| Reported results | 2012-003239-47 | Interventional, open-label, flexible-dose extension study of aripiprazole once-monthly in patients with schizophrenia | 2015-07-01 | due-trials |
| Reported results Terminated | 2012-004169-42 | Interventional, open-label, long-term extension study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in patients with major depressive disorder. | 2014-04-01 | due-trials |
| Reported results | 2012-004763-45 | Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil; study 1 Randomizované dvojit... | 2016-07-19 | due-trials |
| Reported results | 2012-004764-22 | Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil; Study 2 | 2017-07-08 | due-trials |
| Reported results | 2012-004765-40 | Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3 | 2017-01-12 | due-trials |
| Reported results Terminated | 2012-004982-41 | Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose study of brexpiprazole as adjunctive treatment to paroxetine or sertraline in adult patients suffering from ... | 2015-10-30 | due-trials |
| Reported results | 2013-000001-23 | An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease | 2017-07-06 | due-trials |
| Reported results | 2013-001154-98 | Interventional, randomized, double-blind, cross-over, placebo-controlled study to investigate the effects of nalmefene after single dose on the blood oxygen level dependent (BOLD) fMRI signal in the v... | 2014-10-30 | due-trials |
| Reported results | 2013-004688-30 | Interventional, open-label study of 18 mg Selincro® as needed use, in the treatment of patients with alcohol dependence in primary care | 2016-02-23 | due-trials |
| Reported results | 2014-000229-19 | An interventional, randomised, double-blind, parallel-group, placebo-controlled study on the efficacy of vortioxetine on cognitive dysfunction in patients with partial or full remission of major depre... | 2016-04-25 | due-trials |
| Reported results | 2014-000230-34 | An interventional, randomised, double-blind, parallel-group, placebo-controlled, active-referenced (paroxetine), fixed-dose study on the efficacy of vortioxetine on cognitive dysfunction in working pa... | 2016-02-05 | due-trials |
| Reported results | 2014-000231-16 | An interventional, randomised, double-blind, parallel-group, active-comparator, flexible-dose study on the efficacy of vortioxetine versus escitalopram on cognitive dysfunction in patients with inadeq... | 2016-03-01 | due-trials |
| Reported results | 2014-000413-31 | Exploratory, interventional, open-label, fixed-dose study with Selincro® as-needed use, in alcohol dependent patients with liver impairment | 2015-12-04 | due-trials |
| Reported results | 2014-003547-35 | Interventional, open-label, flexible-dose, long-term study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in elderly patients with major depressive disorder with an i... | 2016-06-01 | due-trials |
| Reported results | 2014-003569-12 | Interventional, randomised, double-blind, active-controlled, fixed-dose study of Lu AF35700 in patients with Treatment-resistant Schizophrenia | 2018-10-18 | due-trials |
| Reported results | 2015-002658-11 | Long-term, open-label, flexible-dose, continuation extension study with vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 17 years of age | 2020-04-16 | due-trials |
| Reported results | 2015-003284-11 | Interventional, open-label, flexible-dose, long-term safety study of Lu AF35700 in adult patients with schizophrenia | 2019-12-10 | due-trials |
| Reported results | 2015-005081-30 | Interventional, randomised, double-blind, parallel-group study of the efficacy and safety of initial administration of 17 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patients w... | 2017-04-27 | due-trials |
| Reported results | 2017-000788-34 | Interventional, randomized, double-blind, active-controlled study of the efficacy of Lu AF35700 in patients with early-in-disease or late-in-disease treatment-resistant schizophrenia | 2019-02-05 | due-trials |
| Reported results | 2017-004829-33 | Interventional, open-label, flexible-dose study of vortioxetine on emotional functioning in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment | 2020-02-21 | due-trials |
| Reported results | 2018-000992-34 | Interventional, randomized, double-blind, placebo-controlled study of the efficacy and safety of initial administration of 25 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patien... | 2019-08-28 | due-trials |
| Reported results | 2018-001581-42 | Interventional, randomized, double-blind, parallel-group, placebo-controlled, fixed-flexible-dose study of Lu AF11167 for the treatment of persistent prominent negative symptoms in patients with schiz... | 2020-09-03 | due-trials |
| Reported results | 2018-002708-15 | Interventional, open-label, flexible-dose, long-term safety extension study of Lu AF11167 in patients with schizophrenia | 2020-09-14 | due-trials |
| Reported results | 2019-001325-27 | Interventional, open-label effectiveness study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder comorbid with generalized anxiety disorder Estudio... | 2021-03-09 | due-trials |
| Ongoing, reported early | 2019-001326-10 | Interventional, open-label study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder and early dementia Estudio intervencionista sin enmascaramiento ... | not-yet-due | |
| Reported results | 2019-002704-41 | A randomised, double-blind, parallel-group, active controlled study evaluating the efficacy of vortioxetine versus desvenlafaxine in adult patients suffering from major depressive disorder with partia... | 2022-02-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-004497-25 | Interventional, randomized, double-blind, parallel-group, placebo-controlled study with an extension period to evaluate the efficacy and safety of eptinezumab for the prevention of migraine in patient... | 2023-02-23 | bad-data |
| Ongoing | 2020-001009-22 | Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of ch... | not-yet-due | |
| Other | 2020-001649-38 | Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine | not-yet-due | |
| Ongoing | 2020-001657-42 | Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of eptinezumab for the preventive treatment of migraine Estudio intervencionista, ... | not-yet-due | |
| Reported results | 2020-001669-35 | Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of migraine in patients with a dual d... | 2022-09-30 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-001968-28 | Interventional, open-label, fixed-dose multiple administration study to evaluate long-term treatment with eptinezumab in patients with chronic cluster headache | 2023-06-29 | bad-data |
| Completed, report not yet due | 2020-001969-37 | Interventional, randomized, double-blind, parallel-group, placebo-controlled delayed-start study to evaluate the efficacy and safety of eptinezumab in patients with episodic Cluster Headache | 2023-10-05 | not-yet-due |
| Completed, reported early | 2020-005924-12 | Interventional, randomised, double-blind, parallel-group, placebo-controlled study of Lu AG09222 for the prevention of migraine in patients with unsuccessful prior preventive treatments Intervenční... | 2023-03-16 | not-yet-due |
| Other | 2021-003049-40 | Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in patient... | not-yet-due | |
| Trial is outside EEC, and reported results | 2022-004102-29 | An open-label, single-dose, pharmacokinetic study to evaluate IV eptinezumab in children and adolescents with migraine, followed by an optional, multiple-dose, open-label extension period | bad-data |